AI start­up BioX­cel Ther­a­peu­tics shoots for $69M IPO with drugs for Alzheimer's, can­cer

A new ar­ti­fi­cial in­tel­li­gence start­up is toe­ing the IPO wa­ters, an­nounc­ing plans for a $69 mil­lion pub­lic of­fer­ing that may test in­vestors’ ap­petite for risk.

BioX­cel Ther­a­peu­tics, found­ed less than a year ago, says it’s ap­ply­ing big da­ta and ma­chine learn­ing to its hunt for new ther­a­peu­tics. The com­pa­ny is tak­ing a “re-in­no­va­tion ap­proach,” ap­ply­ing its pro­pri­etary al­go­rithms to ex­ist­ing ap­proved drugs and clin­i­cal­ly val­i­dat­ed prod­uct can­di­dates to find op­por­tu­ni­ties to tweak or im­prove the ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER